奥沙利铂联合卡培他滨术前同步放化疗治疗中晚期直肠癌的临床效果观察  

Clinical effect of preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine in treatment of patients with medium to advanced rectal cancer

作　　者：李红志[1] 王宏刚[2] LI Hongzhi;WANG Honggang(Department of Oncology,Taizhou People's Hospital,Taizhou,Jiaaasu,225305;Department of Intestinal Surgery,Taizhou People's Hospital,Taizhou,Jiaaasu,225305)

机构地区：[1]江苏省泰州市人民医院肿瘤科,江苏泰州225300 [2]江苏省泰州市人民医院肠外科,江苏泰州225300

出　　处：《实用临床医药杂志》2019年第23期51-54,共4页Journal of Clinical Medicine in Practice

摘　　要：目的探讨奥沙利铂联合卡培他滨术前同步放化疗治疗中晚期直肠癌的临床效果。方法选取70例中晚期直肠癌患者,随机分为2组各35例。对照组给予卡培他滨术前同步放化疗治疗,观察组采用奥沙利铂联合卡培他滨术前同步放化疗。2组均随访12个月,观察2组的临床效果。结果观察组临床总有效率为82.86%,显著高于对照组57.14%(P<0.05);观察组术后1年内局部复发率20.00%,显著低于对照组42.86%(P<0.05);观察组术后1年内生存率82.86%,显著高于对照组60.00%(P<0.05);观察组在生理、心理、社会和环境等4个领域的生活质量评分均显著高于对照组(P<0.05)。2组患者不良反应发生情况无显著差异(P>0.05)。观察组与对照组术后1年内远处转移率分别为14.29%、31.43%,差异无统计学意义(P>0.05)。结论奥沙利铂联合卡培他滨术前同步放化疗治疗中晚期直肠癌可明显降低局部复发率,提高患者生活质量。Objective To explore the clinical effect of preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine in treatment of patients with medium to advanced rectal cancer.Methods Seventy patients with medium to advanced rectal cancer were randomly divided into two groups,with 35 cases in each group.The control group was treated with preoperative concurrent chemoradiotherapy by capecitabine,and the observation group received oxaliplatin plus capecitabine for preoperative concurrent chemoradiotherapy.Both groups were followed up for 12 months,and the clinical effects were observed in two groups.Results The total effective rate was 82.86%in the observation group,which was significantly higher than 57.14%in the control group(P<0.05).The local recurrence rate within 1 year after operation in the observation group was 20.00%,which was significantly lower than 42.86%in the control group(P<0.05).The survival rate was 82.86%in the observation group,which was significantly higher than 60.00%in the control group(P<0.05).In the comparison of quality of life,the scores of the four dimensions such as physiological,psychological,social and environmental abilities in the observation group were significantly higher than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The distant metastasis rate of the observation group and the control group within 1 year was 14.29%and 31.43%,respectively(P>0.05).Conclusion Preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine is effective in the treatment of medium to advanced rectal cancer,which can significantly reduce the local recurrence rate and improve the quality of life.

关 键 词：同步放化疗 中晚期直肠癌 奥沙利铂 卡培他滨 复发率 疗效 

分 类 号：R735.3[医药卫生—肿瘤]